What is Integrium?
Headquartered in Tustin, California, with additional operations in Cedar Knolls, New Jersey, Integrium functions as a specialized clinical proof of concept organization. Since its inception in 1998, the firm has served as a vital partner for micro-cap, small-cap, and privately held biotechnology companies. By facilitating the acquisition of robust clinical data, Integrium enables its clients to navigate the complex regulatory environment of the generic and innovator drug sectors. The company maintains a diverse therapeutic focus, spanning high-impact areas such as Cardiovascular, Metabolic, Renal, and Gene Therapy, while also providing specialized expertise in Schedule 2 drugs and Oncology. This comprehensive service model positions Integrium as an essential intermediary in the drug development lifecycle, bridging the gap between early-stage research and commercial viability.
Keywords: Integrium, clinical proof of concept, biotech investment, drug development services, clinical research organization, therapeutic innovation, capital financing, pharmaceutical consulting.
How much funding has Integrium raised?
Integrium has raised a total of $956K across 2 funding rounds:
Debt
$350K
Debt
$606K
Debt (2020): $350K with participation from PPP
Debt (2021): $606K led by PPP
Key Investors in Integrium
PPP
Public-Private Partnership
What's next for Integrium?
With the recent infusion of capital, Integrium is well-positioned to scale its clinical trial infrastructure and enhance its service delivery for complex therapeutic indications. The strategic allocation of these funds will likely focus on expanding the firm's reach within the orphan disease and gene therapy markets, where demand for specialized clinical data remains high. By leveraging this financial backing, Integrium aims to further solidify its reputation as a premier partner for biotech entities seeking to accelerate their path to market. Future growth will likely involve deepening its expertise in oncology and advanced drug delivery systems, ensuring the firm remains at the forefront of clinical innovation while maintaining its commitment to high-quality data integrity for its diverse client base.
See full Integrium company page
